LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

Twist Bioscience Corp

Closed

SectorHealthcare

27.98 3.9

Overview

Share price change

24h

Current

Min

27.57

Max

28.44

Key metrics

By Trading Economics

Income

60M

20M

Sales

3.3M

96M

Profit margin

21.227

Employees

923

EBITDA

22M

-24M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+40.45% upside

Dividends

By Dow Jones

Next Earnings

17 Nov 2025

Market Stats

By TradingEconomics

Market Cap

-258M

1.6B

Previous open

24.08

Previous close

27.98

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

18 Sept 2025, 23:56 UTC

Hot Stocks

Stocks to Watch: FedEx, 22nd Century, Scholastic

18 Sept 2025, 22:01 UTC

Major Market Movers

22nd Century Group Shares Gain on Debt Repayment, New Capital

18 Sept 2025, 20:51 UTC

Acquisitions, Mergers, Takeovers

UPS Terminates Plan to Buy Estafeta

18 Sept 2025, 20:31 UTC

Earnings

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping -- Update

18 Sept 2025, 20:26 UTC

Earnings

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping

18 Sept 2025, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 Sept 2025, 23:43 UTC

Market Talk

Nikkei May Rise on U.S. Stock Gains, Weaker Yen -- Market Talk

18 Sept 2025, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

18 Sept 2025, 23:40 UTC

Market Talk

Gold Edges Lower Amid Cautious Mood -- Market Talk

18 Sept 2025, 23:31 UTC

Market Talk

FedEx Says U.S. Demand Is Resilient -- Market Talk

18 Sept 2025, 22:03 UTC

Earnings

FedEx Expects Trade Environment to Create $1B Headwind in 2026, CFO Says

18 Sept 2025, 22:01 UTC

Earnings

FedEx CFO: Asia-to-U.S. Declines Drove $150M International Export Headwind

18 Sept 2025, 21:56 UTC

Earnings

Lennar Missed Revenue Estimates. The Stock Is Down. -- Barrons.com

18 Sept 2025, 21:54 UTC

Earnings

FedEx Focused on Demand From Southeast Asia, Europe Amid China Shipping Slowdown, Customer Chief Says

18 Sept 2025, 21:48 UTC

Earnings

FedEx International Export Volumes Declined, Especially on China-to-U.S. Lane, Exec Says

18 Sept 2025, 21:47 UTC

Earnings

FedEx Had 5% Increase in U.S. Domestic Average Daily Package Volume in 1Q, Customer Chief Says

18 Sept 2025, 21:17 UTC

Earnings

FedEx Profit, Sales Rise on Improvement in U.S. Shipping -- 2nd Update

18 Sept 2025, 21:07 UTC

Earnings

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 Sept 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18 Sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 Sept 2025, 20:50 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

18 Sept 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

18 Sept 2025, 20:22 UTC

Acquisitions, Mergers, Takeovers

UPS Cites Inability of All Closing Conditions to Be Satisfied

18 Sept 2025, 20:22 UTC

Acquisitions, Mergers, Takeovers

United Parcel Service Terminates Plan to Buy Estafeta

18 Sept 2025, 20:20 UTC

Acquisitions, Mergers, Takeovers

Here's How Much the U.S. Has Made on Its Intel Stock Purchase -- Barrons.com

18 Sept 2025, 20:18 UTC

Earnings

Nucor Stock Falls After Earnings. Why Its Guidance Was Far Off Rival Steel Dynamics. -- Barrons.com

18 Sept 2025, 20:18 UTC

Earnings

Bullish Crushes Earnings. The Crypto Stock Pops. -- Barrons.com

18 Sept 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 Sept 2025, 20:07 UTC

Earnings

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 Sept 2025, 20:03 UTC

Earnings

FedEx 1Q FedEx Freight Segment Revenue $2.26B >FDX

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

40.45% upside

12 Months Forecast

Average 37.88 USD  40.45%

High 50 USD

Low 25 USD

Based on 9 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

6

Buy

2

Hold

1

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat